8 results match your criteria pet-driven strategy

  • Page 1 of 1

Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).

J Clin Oncol 2021 Jun 22:JCO2100068. Epub 2021 Jun 22.

Department of Haematology, University Hospital F Mitterrand and Inserm UMR1231, Dijon, France.

Purpose: The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) in early responders on the basis of a positron emission tomography (PET)-driven strategy was safe and minimized toxicity compared with standard 6 BEACOPP cycles. This substudy investigated the benefit of this strategy in gonadal function and fertility in patients under 45 years old.

Methods: Ovarian function was assessed by serum measurement of follicle-stimulating hormone (FSH), estradiol, and anti-müllerian hormone in women, and semen analysis, FSH, and testosterone levels were used to evaluate testicular function in men at baseline, end of treatment, and during 5 years of follow-up. Read More

View Article and Full-Text PDF

Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.

Hematol Oncol 2020 Oct 30;38(4):501-508. Epub 2020 Jul 30.

Department of Oncology and Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). Read More

View Article and Full-Text PDF
October 2020

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Lancet Oncol 2019 02 15;20(2):202-215. Epub 2019 Jan 15.

LYSA Imaging, Hôpital H Mondor, Creteil, France.

Background: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPP to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring.

Methods: AHL2011 is a randomised, non-inferiority, phase 3 study done in 90 centres across Belgium and France. Read More

View Article and Full-Text PDF
February 2019

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

J Clin Oncol 2018 02 23;36(5):454-462. Epub 2018 Jan 23.

Andrea Gallamini, Centre Antoine Lacassagne, Nice, France; Corrado Tarella, Istituto Europeo di Oncologia; Daniela Gottardi, Ospedale Mauriziano Umberto I di Torino; Paolo Gavarotti, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Simonetta Viviani and Paolo Corradini, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Paolo Corradini, Alessandro Massimo Gianni, and Alessandro Rambaldi, Università degli Studi di Milano; Andrés J.M. Ferreri and Federico Fallanca, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele; Giuseppe Prosperini, Istituto di Ricovero e Cura a Carattere Scientifico-Istituto di Ricerche Farmacologiche Mario Negri, Milan; Andrea Rossi, Chiara Pavoni, and Alessandro Rambaldi, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; Caterina Patti and Antonino Mulé, Azienda Villa Sofia-Cervello; Umberto Ficola, La Maddalena, Palermo; Marco Picardi, Università Federico II, Naples; Alessandra Romano, Ospedale Ferrarotto, Catania; Maria Cantonetti, Policlinico Tor Vergata; Roberta Battistini, Ospedale San Camillo; Agostino Chiaravalloti, Università Tor Vergata, Rome; Giorgio La Nasa, Ospedale Roberto Binaghi di Cagliari, Cagliari; Livio Trentin, Università di Padova, Padua; Silvia Bolis, Ospedale San Gerardo, Monza; Davide Rapezzi, Alberto Biggi, Fabrizio Bergesio, and Stephane Chauvie, Azienda Ospedaliera Santa Croce e Carle, Cuneo; Michele Cimminiello, Ospedale San Carlo, Potenza; Corrado Schiavotto, Presidio Ospedaliero San Bortolo, Vicenza; Guido Parvis, Azienda Ospedaliera San Luigi, Orbassano; Roberta Zanotti, Azienda Ospedaliera Universitaria Integrata, Verona; Guido Gini, Nuovo Ospedale Torrette, Ancona; Piera Viero, Ospedale dell'Angelo, Mestre; Maurizio Miglino, Azienda Ospedaliera Universitaria San Martino, Genoa; Atto Billio, Ospedale Centrale di Bolzano, Bolzano; Michele Gregianin, Ospedale San Giacomo, Castelfranco Veneto, Italy; and Abraham Avigdor, Chaim Sheba Medical Center, Tel HaShomer, Israel.

Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive positron emission tomography scan performed after two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles (PET2). Patients and Methods Patients with advanced-stage (IIB to IVB) HL were consecutively enrolled. After two ABVD cycles, PET2 was performed and centrally reviewed according to the Deauville five-point scale. Read More

View Article and Full-Text PDF
February 2018

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Blood 2017 09 12;130(11):1315-1326. Epub 2017 Jul 12.

Department of Hematology, Hôpital Claude Huriez, Université Lille, EA 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Dose-dense induction and up-front consolidation with autologous stem cell transplantation (ASCT) remain controversial issues when treating patients with high-risk diffuse large B-cell lymphoma. GELA designed a randomized phase 2 trial evaluating the efficacy of either rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) or rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14) induction and a positron emission tomography (PET)-driven ASCT or standard immunochemotherapy (SIC) consolidation in age-adjusted international prognosis index 2 (aaIPI2)-aaIPI3 patients. PET was performed at baseline, after 2 (PET2) and 4 (PET4) induction cycles, and centrally assessed using international harmonization project (IHP) criteria. Read More

View Article and Full-Text PDF
September 2017

Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

Blood 2017 06 17;129(23):3059-3070. Epub 2017 Apr 17.

Department of Hematology, CHU de Dijon, University Hospital of Dijon, Dijon, France; and.

F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) has become a central tool for both accurate initial staging and determination of prognosis after treatment of diffuse large B-cell lymphoma (DLBCL). However, the role of PET during treatment (iPET) in daily practice remains a matter of significant debate. This perspective reviews the published studies on iPET in DLBCL, including the methods used to analyze iPET, its timing, and studies of iPET-driven therapy to illuminate where daily practice may benefit from the use of iPET. Read More

View Article and Full-Text PDF

[Current questions in the radiotherapy of lymphoproliferative tumors].

József Lövey

Magy Onkol 2017 Mar 27;61(1):97-104. Epub 2017 Jan 27.

Sugárterápiás Központ, Országos Onkológiai Intézet, Budapest, Hungary.

Radiation therapy traditionally plays a major role in the treatment of lymphoproliferative diseases. Diagnostics and treatment of these tumors improved tremendously in the recent decades. Molecular diagnostics is able to discriminate its subtypes more precisely than ever and opens the possibility of the introduction of targeted medicines. Read More

View Article and Full-Text PDF

Lymph-node relapsed prostate cancer management and PET-driven external beam radiotherapy: salvage or palliative treatment?

Q J Nucl Med Mol Imaging 2015 Dec 1;59(4):411-9. Epub 2015 Sep 1.

Radiotherapy Unit, Humanitas Gavazzeni, Bergamo, Italy -

New imaging modalities such as choline- positron emission tomography (PET) or PET/computed tomography (CT) may be useful to identify prostate cancer patients with small volume, limited nodal relapse ("oligo-recurrent"), potentially amenable to metastasis directed treatment (e.g. radiotherapy,) with the aim of long-term control of the disease, even in a setting traditionally considered prognostically unfavorable, so usually gone to palliative treatment. Read More

View Article and Full-Text PDF
December 2015
  • Page 1 of 1